



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

14<sup>th</sup> November, 2022

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

**Kind Attn: General Manager-DCS**

Scrip Code: **533543**

**Kind Attn: Head- Listing**

Symbol: **BROOKS**

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2<sup>nd</sup> quarter and half yearly ended 30<sup>th</sup> September, 2022. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement as at 30.09.2022 together with the Limited Review Report are attached.

The Board meeting commenced at 4:00 pm (IST) and concluded at 6:20 pm (IST).

This is for your information and record.

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

RAJESH  
MAHAJAN  
Digitally signed  
by RAJESH  
MAHAJAN  
Date: 2022.11.14  
18:20:49 +05'30'

**Rajesh Mahajan**

**Managing Director**

**Din No. 02000634**

Encl.: As Stated above



**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net

(Rs. In Lakhs)


**Statements of Unaudited Financial Results for the Quarter & Half year ended 30th September, 2022.**

Particulars	Standalone						Consolidated					
	Quarter Ended			Half year ended			Quarter Ended			Half year ended		
	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22
	Unaudited			Unaudited			Audited	Unaudited			Unaudited	
<b>1 Income</b>												
Revenue from operations	1,589.49	1,494.28	2,105.08	3,083.77	3,753.20	7,696.72	1,808.09	1,712.36	2,146.21	3,520.45	4,360.71	9,107.72
Other Income	6.51	4.62	34.43	11.13	36.68	94.76	13.70	3.41	10.57	17.11	35.80	90.91
<b>Total income</b>	<b>1,596.00</b>	<b>1,498.90</b>	<b>2,139.51</b>	<b>3,094.90</b>	<b>3,789.88</b>	<b>7,791.48</b>	<b>1,821.79</b>	<b>1,715.77</b>	<b>2,156.78</b>	<b>3,537.56</b>	<b>4,396.51</b>	<b>9,198.63</b>
<b>2 Expenses</b>												
(a) Cost of materials consumed	835.73	834.62	825.15	1,670.35	1,742.36	4,648.83	2,116.56	1,449.66	1,057.43	3,566.22	2,496.98	6,293.45
(b) Purchase of Stock in Trade	191.01	279.09	100.63	470.10	402.22	571.65	86.48	279.09	100.56	365.57	119.23	195.85
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	87.19	136.69	424.80	223.88	73.84	(292.56)	(729.36)	(112.85)	413.73	(842.21)	311.68	(210.47)
(d) Employees benefits expenses	279.93	354.99	319.39	634.92	611.60	1,280.19	522.35	571.15	458.03	1,093.51	870.31	1,914.95
(e) Finance Costs	18.51	15.71	12.39	34.22	30.52	66.97	62.83	62.29	75.18	125.13	151.29	309.69
(f) Depreciation and amortization expenses	42.95	42.34	35.01	85.29	70.75	148.63	227.99	198.21	173.51	426.20	351.71	735.07
(g) Other expenses	222.57	292.47	316.25	515.03	610.39	1,301.17	734.59	385.22	531.29	1,119.81	969.35	2,349.86
<b>Total Expenses</b>	<b>1,677.89</b>	<b>1,955.91</b>	<b>2,033.62</b>	<b>3,633.79</b>	<b>3,541.68</b>	<b>7,724.88</b>	<b>3,021.44</b>	<b>2,832.77</b>	<b>2,809.73</b>	<b>5,854.23</b>	<b>5,270.55</b>	<b>11,588.40</b>
<b>3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax</b>	<b>(81.89)</b>	<b>(457.01)</b>	<b>105.89</b>	<b>(538.89)</b>	<b>248.20</b>	<b>66.60</b>	<b>(1,199.65)</b>	<b>(1,117.00)</b>	<b>(652.95)</b>	<b>(2,316.67)</b>	<b>(874.04)</b>	<b>(2,389.77)</b>
<b>4 Share of Profit / (Loss) of Associate</b>	-	-	-	-	-	-	26.51	-	(12.59)	26.51	-	-
<b>Profit/(Loss) before Exceptional item and tax</b>	<b>(81.89)</b>	<b>(457.01)</b>	<b>105.89</b>	<b>(538.89)</b>	<b>248.20</b>	<b>66.60</b>	<b>(1,173.14)</b>	<b>(1,117.00)</b>	<b>(665.54)</b>	<b>(2,290.16)</b>	<b>(874.04)</b>	<b>(2,389.77)</b>
<b>5 Exceptional Items</b>	-	-	-	-	-	-	-	-	-	-	-	-
<b>6 Profit/(Loss) from ordinary activities before tax</b>	<b>(81.89)</b>	<b>(457.01)</b>	<b>105.89</b>	<b>(538.89)</b>	<b>248.20</b>	<b>66.60</b>	<b>(1,173.14)</b>	<b>(1,117.00)</b>	<b>(665.54)</b>	<b>(2,290.16)</b>	<b>(874.04)</b>	<b>(2,389.77)</b>
<b>7 Tax Expense:</b>												
Deferred Tax Liability / (Assets)	-	-	-	-	-	-	(385.48)	(177.25)	(182.48)	(562.73)	(276.73)	(458.51)
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	-	-	-	-	-	-	-
<b>8 Net Profit/(loss) after tax</b>	<b>(81.89)</b>	<b>(457.01)</b>	<b>105.89</b>	<b>(538.89)</b>	<b>248.20</b>	<b>66.60</b>	<b>(787.66)</b>	<b>(939.75)</b>	<b>(483.06)</b>	<b>(1,727.43)</b>	<b>(597.31)</b>	<b>(1,931.26)</b>
<b>9 Other Comprehensive Income</b>												
<b>Items That will not be reclassified into Profit or loss</b>												
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	-	(2.95)	-	(5.91)	8.85	-	-	(2.96)	-	(5.91)	2.73
Gain on remeasuring FVTPL financial assets	-	-	-	-	-	3.81	-	-	-	-	-	3.81
<b>10 Total Comprehensive income for the period</b>	<b>(81.89)</b>	<b>(457.01)</b>	<b>102.94</b>	<b>(538.89)</b>	<b>242.29</b>	<b>79.26</b>	<b>(787.66)</b>	<b>(939.75)</b>	<b>(486.02)</b>	<b>(1,727.43)</b>	<b>(603.22)</b>	<b>(1,924.72)</b>
<b>Net Profit attributable to</b>												
Owners of equity	-	-	-	-	-	-	(468.20)	(690.06)	(483.06)	(1,158.26)	(597.31)	(1,618.75)
Non Controlling Interest	-	-	-	-	-	-	(319.48)	(249.69)	-	(569.17)	-	(312.51)
<b>Other Comprehensive Income attributable to</b>												
Owners of equity	-	-	-	-	-	-	-	-	(2.96)	-	(5.91)	9.01
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	(2.47)
<b>Total Comprehensive Income attributable to</b>												
Owners of Equity	-	-	-	-	-	-	(468.20)	(690.06)	(486.02)	(1,158.26)	(603.22)	(1,609.74)
Non Controlling Interest	-	-	-	-	-	-	(319.48)	(249.69)	-	(569.17)	-	(314.98)
<b>11 Paid-up equity share capital (Face Value of Rs. 10 each)</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>
<b>12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.</b>	<b>4,030.02</b>	<b>4,030.02</b>	<b>3,950.76</b>	<b>4,030.02</b>	<b>3,950.76</b>	<b>3,950.76</b>	<b>6,278.72</b>	<b>6,278.72</b>	<b>5,444.56</b>	<b>6,278.72</b>	<b>5,444.56</b>	<b>5,444.56</b>
<b>13 Earnings per share (of Rs. 10/- each) (not annualised)</b>												
(a) Basic	(0.33)	(1.85)	0.42	(2.18)	0.98	0.27	(3.19)	(3.80)	(1.97)	(6.99)	(2.44)	(7.82)
(b) Diluted	(0.33)	(1.85)	0.42	(2.18)	0.98	0.27	(3.19)	(3.80)	(1.97)	(6.99)	(2.44)	(7.82)

**Notes:**

- The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 14th November, 2022
- The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- The Company operates in one reportable business segment i.e. "Pharmaceuticals".
- Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board

 Rajesh Mahajan  
 Din : 02000634  
 Managing Director

 Place : Mumbai  
 Date : 14th November, 2022



**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net

**Statement of Assets & Liabilities as at 30th September, 2022**

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	As at September 30, 2022 (Un audited)	As at March 31, 2022 (Audited)	As at September 30, 2022 (Un audited)	As at March 31, 2022 (Audited)
<b>A ASSETS</b>				
<b>1 Non Current Assets</b>				
(a) Property, Plant and Equipment	1,327.86	1,371.55	10,870.19	10,832.25
(b) Capital work in progress	122.93	112.10	2,461.52	1,510.74
(c) Right to use Assets	92.66	106.03	92.66	106.03
(d) Intangible asset	26.47	36.08	433.68	63.08
(f) Financial Assets				
(i) Investments	4,684.35	4,684.35	32.32	5.81
(ii) Security deposit	82.07	81.77	136.10	125.72
(ii) Other Financial Assets	24.95	21.96	61.18	21.96
(g) Income Tax Assets (Net)	239.21	228.04	239.21	232.06
(h) Deferred tax assets/(liability) (net)	-	-	698.25	135.52
(i) Other Non Current Assets	-	-	589.34	439.70
<b>Total Non - Current Assets</b>	<b>6,600.50</b>	<b>6,641.88</b>	<b>15,614.45</b>	<b>13,472.87</b>
<b>2 Current assets</b>				
(a) Inventories	1,167.87	1,658.76	2,189.04	2,752.24
(b) Financial Assets				
(i) Trade receivables	1,273.43	1,503.49	1,585.46	1,766.23
(ii) Security Deposit			10.00	10.00
(ii) Cash and Cash Equivalents	4.96	8.38	8.52	260.50
(iii) Bank Balances other than cash & cash equivalents	79.89	99.26	101.13	120.50
(iv) Other Financial Assets	131.40	133.88	134.63	136.87
(c) Other Current Assets	211.07	299.75	1,335.13	1,071.85
<b>Total Current Assets</b>	<b>2,868.62</b>	<b>3,703.52</b>	<b>5,363.91</b>	<b>6,118.19</b>
<b>TOTAL ASSETS</b>	<b>9,469.12</b>	<b>10,345.40</b>	<b>20,978.36</b>	<b>19,591.06</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 Equity</b>				
(a) Equity Share Capital	2,470.28	2,470.28	2,470.28	2,470.28
(b) Other Equity	3,491.11	4,030.01	5,550.75	6,278.72
<b>Equity attributable to Owners of the Company</b>	<b>5,961.39</b>	<b>6,500.29</b>	<b>8,021.03</b>	<b>8,749.00</b>
Non-Controlling interests	-	-	5,858.83	4,682.94
<b>Total Equity</b>	<b>5,961.39</b>	<b>6,500.29</b>	<b>13,879.86</b>	<b>13,431.94</b>
<b>Liabilities</b>				
<b>2 Non-current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	-	-	732.64	929.05
(ii) Lease Liability	72.84	84.88	72.85	84.88
(iii) Other Financial Liabilities	53.90	48.90	45.00	40.00
(b) Deferred Tax Liabilities	-	-	-	-
(b) Provisions	173.13	164.86	240.04	217.33
<b>Total Non - Current Liabilities</b>	<b>299.87</b>	<b>298.64</b>	<b>1,090.53</b>	<b>1,271.26</b>
<b>3 Current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	502.57	492.29	1,523.61	1,492.22
(ii) Lease liability	22.13	19.70	22.13	19.70
(iii) Trade Payables				
- Due to micro and small enterprises	1,240.87	1,447.17	2,111.44	1,214.20
- Due to Others	1,046.25	1,127.53	1,621.12	1,585.81
(iii) Other Financial Liabilities	162.58	167.89	231.32	254.69
(b) Other current liabilities	140.52	217.94	348.59	217.96
(c) Provisions	92.94	73.95	149.76	103.28
<b>Total Current Liabilities</b>	<b>3,207.86</b>	<b>3,546.47</b>	<b>6,007.97</b>	<b>4,887.86</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>9,469.12</b>	<b>10,345.40</b>	<b>20,978.36</b>	<b>19,591.06</b>

For Brooks Laboratories Limited

Place : Mumbai  
Date : 14th November, 2022Rajesh Mahajan  
Din : 02000634  
Managing Director



**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939

**Cash Flow Statement for the half year ended 30th September, 2022**

(Rs. In Lakhs)


Particulars	Standalone		Consolidated	
	Year ended 30 September 2022	Year ended 31 March 2022	Year ended 30 September 2022	Year ended 31 March 2022
	UnAudited	Audited	UnAudited	Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net (loss) / profit before tax	(538.90)	66.59	(2,290.15)	(2,389.77)
<b>Adjustments for</b>				
Depreciation and amortisation expense	85.29	148.63	426.20	735.07
Finance cost	29.43	66.97	125.13	309.69
Interest income	(2.16)	(6.19)	(3.43)	(8.77)
Remeasurement of Defined benefit obligations	-	8.85	-	2.73
Dividend from current investments	(0.40)	(0.30)	(0.40)	(0.30)
Share of profit from Associate	-	-	(26.51)	-
Profit on sale of asset	-	(28.10)	-	(13.10)
Loss on discarded asset	-	2.15	-	-
Liability no longer payable	-	(22.26)	-	(22.26)
Bad debts recovered	-	(10.74)	-	(10.74)
Provision for Expected credit loss	16.84	92.87	16.84	92.87
Unrealised Foreign Exchange Gain	-	0.44	0.47	22.21
<b>Operating profit before working capital changes</b>	<b>(409.90)</b>	<b>318.91</b>	<b>(1,751.85)</b>	<b>(1,282.33)</b>
<b>Adjustments for changes in working capital:</b>				
Decrease / (increase) in Trade Receivables	213.21	(623.38)	197.61	(500.57)
Decrease / (increase) in Inventories	490.89	(420.89)	563.20	(391.93)
Decrease / (increase) in Other Assets	88.68	(94.29)	(263.27)	(289.81)
Decrease / (increase) in Other Financial Assets	2.18	(73.04)	(11.15)	(76.06)
(Decrease) / Increase in Trade and Other Payables	(287.57)	1,257.92	936.36	(270.05)
(Decrease) / Increase in Other Financial Liabilities	(0.31)	(140.41)	(18.38)	(1,047.53)
(Decrease) / Increase in Other Liabilities	(77.42)	92.20	130.64	91.84
(Decrease) / Increase in Provisions	27.26	21.68	69.20	52.74
<b>Cash generated from / (used in) operations</b>	<b>47.02</b>	<b>338.70</b>	<b>(147.64)</b>	<b>(3,713.70)</b>
Direct taxes paid (net of refunds received)	(11.16)	(26.36)	(7.15)	(30.36)
<b>Net cash (used in) / from generated from operating activities</b>	<b>35.86</b>	<b>312.34</b>	<b>(154.79)</b>	<b>(3,744.06)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchase of property, plant and equipment (including capital work in progress and capital advances)	(29.45)	(176.88)	(1,772.15)	(2,321.53)
Proceeds from sale of property, plant and equipment	-	291.00	-	291.00
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	16.38	(8.46)	(26.85)	(29.71)
Capital Advance	-	-	(149.64)	(439.70)
Interest received	2.16	6.19	3.43	8.78
Dividend received	0.40	0.30	0.40	0.30
<b>Net cash (used in) / generated from investing activities</b>	<b>(10.49)</b>	<b>112.15</b>	<b>(1,944.81)</b>	<b>(2,490.84)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds by Minority Interest	-	-	2,175.30	7,441.85
Proceeds/ (Repayment) from borrowings (net)	10.22	(347.62)	(192.92)	(717.25)
Repayment of Lease Liabilities	(9.61)	(7.89)	(9.62)	(7.90)
Finance costs paid	(29.43)	(66.97)	(125.13)	(309.69)
<b>Net cash (used in) / from financing activities</b>	<b>(28.78)</b>	<b>(422.48)</b>	<b>1,847.63</b>	<b>6,406.99</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(3.42)</b>	<b>2.01</b>	<b>(251.97)</b>	<b>172.11</b>
Cash and cash equivalents at the beginning of the year	8.38	6.37	260.50	88.39
<b>Cash and cash equivalents at the end of the year</b>	<b>4.96</b>	<b>8.38</b>	<b>8.52</b>	<b>260.50</b>

Place: Mumbai

Date : 14th November, 2022

For and on Behalf of Board

Rajesh Mahajan  
Din : 02000634  
Managing Director



# SGCO & Co. LLP

Chartered Accountants

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter and half year ended on September 30, 2022, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,  
The Board of Directors of  
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter and half year ended on September 30, 2022. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co. LLP**

Chartered Accountants

Firm's Registration No. 112081W/W100184

  
Suresh Murarka

Partner

Mem. No. 044739

UDIN : 22044739BDCFYD3353



Place : Mumbai

Date : 14<sup>th</sup> November 2022

4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. [info@sgco.co.in](mailto:info@sgco.co.in)  
[www.sgco.co.in](http://www.sgco.co.in)



# **SGCO & Co. LLP**

## **Chartered Accountants**

Limited Review Report on Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2022 of Brooks Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
**Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
- Brooks Laboratories Limited (Parent Company)
  - Brooks Steriscience Limited (Subsidiary Company)
  - Steribrooks Penems Private Limited (Associate Company)



4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. [info@sgco.co.in](mailto:info@sgco.co.in)  
[www.sgco.co.in](http://www.sgco.co.in)

# SGCO & Co. LLP


Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of one subsidiary vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial results reflect total assets of Rs. 16,655.22 lakhs as at September 30, 2022 and total Income of Rs. 353.75 lakhs and Rs. 638.75 lakhs, total net profit/(loss) after tax of Rs.(641.64) lakhs and Rs. (1220.15) lakhs and total comprehensive income / loss of Rs (641.64) lakhs and Rs. (1220.15) lakhs, for the quarter and half year ended September 30, 2022 respectively, and cash out flows (net) of Rs. 248.55 lakhs for the half year ended September 30, 2022, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. The consolidated financial statements also include the Group's share of net profit of Rs. 26.51 lakhs and Rs.26.51 lakhs for the quarter and half year ended September 30, 2022 respectively, as considered in the consolidated unaudited financial statements, in respect of one associate (Steribrooks Penems Private Limited) whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management.

Our conclusion on the Statement is not modified in respect of the above matters.

**For S G C O & Co. LLP**  
Chartered Accountants  
Firm Registration No. 112081W/W100184

  
Suresh Murarka  
Partner  
Mem. No. 044739  
UDIN : 22044739BDCGOG9901



Place : Mumbai  
Date : 14<sup>th</sup> November, 2022